Chuangsheng Group-B (06628) plans to place 14.4 million shares at a discount of about 18.76% to raise about HK$59.34 million

According to the Zhitong Finance App, Chuangsheng Group-B (06628) announced that on September 10, 2025, the company plans to place 14.4 million shares, accounting for about 3.20% of the total number of shares already issued (excluding treasury shares) after completing the distribution. The placement price was HK$4.33 per share, a discount of approximately 18.76% over the closing price of HK$5.33 per share on September 9.

The total proceeds from the placement are expected to be approximately HK$62.35 million, while the net proceeds are approximately HK$59.34 million. The company plans to use the net proceeds from the subscription in the following ways: (i) 40% for clinical development of pipeline assets such as TST001 and TST002; (ii) 30% to advance the most promising pre-clinical pipeline assets with the potential for immediate external licensing, including TST801, TST013 and TST786; (iii) 30% will be used for working capital and general purposes, thereby improving the company's financial soundness, including but not limited to general business operations and business development.